Published in:
01-02-2020 | Clostridium | Topic Paper
Management of Peyronie’s disease with collagenase Clostridium histolyticum in the acute phase
Published in: World Journal of Urology | Issue 2/2020
Login to get accessAbstract
Introduction
Peyronie’s disease (PD) can affect men of all ages and is associated with penile pain as well as curvature and erectile dysfunction. Treatment modalities for PD include conservative, less invasive and surgical treatments. Choice of treatment depends on the disease’s phase. Injection of collagenase Clostridium histolyticum (CCH) is only the Food and Drug Administration approved treatment for the management of the chronic phase of the disease. Only a few limited studies have evaluated its potential benefits during the acute phase.
Aim
To evaluate the current evidence on the use of injectable CCH during the acute or active phase of PD.
Methods
We performed a PubMed database search for articles published between 2015 and 2018 that investigated the use of CCH for the management of the acute phase of PD. Search keywords included “Peyronie’s disease”, “collagenase Clostridium histolyticum”, and “acute phase”.
Main outcome measures
Changes in penile curvature after treatment with injectable CCH.
Results
Mean curvature decrease ranged between 15.8° and 22.6° corresponding to 27.4–37.4% decrease from baseline after 2.5–4 cycles, corresponding to 5–8 injections, of CCH treatment in patients during the acute phase of PD.
Conclusions
Intralesional CCH injection therapy during the acute phase of PD can be both safe and effective and clinically significant improvements in penile curvature may be achieved. Larger multi-institutional studies are, however, still needed to confirm these results and validate this additional indication for CCH.